

December 22, 2015

---

# **Nemus Enters Into Research Agreement With the University of Mississippi to Develop Cannabinoid-Based Therapies for Chemotherapy-Induced Peripheral Neuropathy (CIPN)**

COSTA MESA, CA -- (Marketwired) -- 12/22/15 -- NEMUS Bioscience, Inc. (OTCQB: NMUS) has entered into a research agreement with the Company's development and commercial partner, the University of Mississippi (UM), to advance specialized cannabinoid derivatives for the management of CIPN. The agreement was executed based on a series of studies using validated animal models of CIPN exposed to unique cannabinoid-based therapies conducted in the lab of Dr. Kenneth J. Sufka, professor of Psychology and Pharmacology and Research Professor with the National Center for Natural Products Research at UM.

"The CIPN market comprises roughly 1.8 million patients among the major global markets and represents a significant unmet medical need. Affected patients represent upwards of 40% of those undergoing chemotherapy and 15%-20% of these patients continue to experience neuropathic pain after cessation of chemotherapy," stated Brian Murphy, MD, MPH, who serves as both NEMUS CEO and CMO. "We believe intervention with specialized cannabinoid derivatives could help optimize the efficacy and safety of chemotherapeutics".

"Therapies for CIPN can often lead to complications including dizziness, confusion, drug tolerance, dependence, and sedation," reports Dr. Sufka. "New treatment regimens are needed to mitigate the risk of adverse events and improve patient outcomes." Dr. Sufka was the recipient of the prestigious CASE-Carnegie U.S. Professor of the Year award in 2014, a national recognition presented to this country's outstanding college faculty.

"Nemus plans to act on significant scientific findings generated by our partner, the University of Mississippi, and with our recent in-licensing of CBD, we plan to leverage these unique cannabinoid derivatives to expand our pipeline, especially into disorders of urgent medical need," said Dr. Murphy. "The CIPN market is estimated to approach \$500 million domestically, while the general neuropathic pain market in the United States afflicts an estimated six million patients generating sales of \$3 billion in attempts to manage the disease. There is currently no specific treatment for neuropathy as therapy centers around palliative care. We feel that cannabinoid-based therapies can be a significant advance in the management of this debilitating adverse event."

## **ABOUT NEMUS BIOSCIENCE, INC.**

The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabis-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to

develop novel ways to deliver cannabis-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS's strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.

For more information, visit [www.nemusbioscience.com](http://www.nemusbioscience.com)

## FORWARD LOOKING STATEMENTS

Statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties, including statements about the potential benefits and developments that may be achieved under the research agreement. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "challenge," "predictable" "will," or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, uncertainty regarding the ability to achieve the expected benefits from the research agreement and other risks that are described in the Risk Factors section of NEMUS' most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements.

Contact:

Investor Relations

Mike Cole

Vice President - MZ North America

Main: 949-259-4988

Mobile: 949-444-1341

[mike.cole@mzgroup.us](mailto:mike.cole@mzgroup.us)

[www.mzgroup.us](http://www.mzgroup.us)

Source: Nemus Bioscience